Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer
Dr Merseburger on Real-World Outcomes With First-Line Axitinib Plus Avelumab in RCC
Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance